Skip to main content
Top
Published in: Rheumatology International 11/2007

01-09-2007 | Case Report

Nephrotic syndrome as a clinical manifestation of systemic sclerosis

Authors: Ewa Wielosz, Maria Majdan, Dorota Suszek, Iwona Smarz-Widelska, Agnieszka Korolczuk, Elżbieta Korobowicz

Published in: Rheumatology International | Issue 11/2007

Login to get access

Abstract

We have described the unusual case of coexistence of membranous nephropathy resulting in nephrotic syndrome with systemic sclerosis. A 60-year-old patient was admitted to the Department of Nephrology with marked proteinuria and oedema. The renal biopsy specimen disclosed the features characteristic of membranous glomerulonephritis. The patient was treated with chlorambucil for 1 month followed by prednisone for 1 month. However, her condition still did not improve. Therefore, the other causes of nephrotic syndrome were investigated. Once anti-Scl-70 antibody was detected the patient was transferred to the Department of Rheumatology and Connective Tissue Diseases. Physical examination revealed Raynaud phenomenon, sclerodactylia, thickened skin of the chest and back. The patient was diagnosed with diffuse systemic sclerosis. The cyclophosphamide therapy was instituted and the patient’s condition improved.
Literature
1.
go back to reference Majdan M, Parada-Turska J, Suszek D (2004) Renal involvement in rheumatic diseases. Polskie Archiwum Medycyny Wewnętrznej 112:167–172 Majdan M, Parada-Turska J, Suszek D (2004) Renal involvement in rheumatic diseases. Polskie Archiwum Medycyny Wewnętrznej 112:167–172
2.
go back to reference Balck C, Denton CP (1998) Scleroderma-systemic sclerosis. In: Davison AM, Cameron JS, Grunfeld JP (eds) Oxford textbook of clinical nephrology. Oxford University Press, New York, pp 961 Balck C, Denton CP (1998) Scleroderma-systemic sclerosis. In: Davison AM, Cameron JS, Grunfeld JP (eds) Oxford textbook of clinical nephrology. Oxford University Press, New York, pp 961
3.
go back to reference Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD, Osial TA, Tolchin SF (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine 62:335–352 Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD, Osial TA, Tolchin SF (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine 62:335–352
4.
go back to reference Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32:649–655PubMed Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32:649–655PubMed
5.
go back to reference Simms RW, Korn JH (2001) Systemic sclerosis; the spectrum immunopathogenesis clinical features, and treatment. In: Adu D, Emery P, Madaio M (eds) Rheumatology and the kidney. Oxford University Press, New York, pp 275 Simms RW, Korn JH (2001) Systemic sclerosis; the spectrum immunopathogenesis clinical features, and treatment. In: Adu D, Emery P, Madaio M (eds) Rheumatology and the kidney. Oxford University Press, New York, pp 275
6.
go back to reference Palma A, Sanchez-Palenica A, Armas JR, Milan JA, Fernandez-Sanz J, Llach F (1981) Progressive systemic sclerosis and nephrotic syndrome. Arch Intern Med 141:520–521PubMedCrossRef Palma A, Sanchez-Palenica A, Armas JR, Milan JA, Fernandez-Sanz J, Llach F (1981) Progressive systemic sclerosis and nephrotic syndrome. Arch Intern Med 141:520–521PubMedCrossRef
7.
go back to reference Kobayashi Y, Muraoka M, Tojo T (1977) Progressive systemie sclerosis sine scleroderma with nephrotic syndrome and suspected renal tubular acidosis. Nippon Naika Gakkai Zasshi 66:186–189 Kobayashi Y, Muraoka M, Tojo T (1977) Progressive systemie sclerosis sine scleroderma with nephrotic syndrome and suspected renal tubular acidosis. Nippon Naika Gakkai Zasshi 66:186–189
8.
go back to reference Bourne FM, Howell DA, Root HS (1960) Renal and cerebral scleroderma. Can Med Assoc J 82:881–886PubMed Bourne FM, Howell DA, Root HS (1960) Renal and cerebral scleroderma. Can Med Assoc J 82:881–886PubMed
9.
go back to reference Rihova Z, Honsova E, Merta M, Jancova E, Rysava R, Reiterova J, Zabka J, Tesar V (2005) Secondary membranous nephropathy—one center experience. Ren Fail 27:397–402PubMed Rihova Z, Honsova E, Merta M, Jancova E, Rysava R, Reiterova J, Zabka J, Tesar V (2005) Secondary membranous nephropathy—one center experience. Ren Fail 27:397–402PubMed
10.
go back to reference Jefferson JA Couser WG (2003) Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 23:400–405CrossRef Jefferson JA Couser WG (2003) Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 23:400–405CrossRef
Metadata
Title
Nephrotic syndrome as a clinical manifestation of systemic sclerosis
Authors
Ewa Wielosz
Maria Majdan
Dorota Suszek
Iwona Smarz-Widelska
Agnieszka Korolczuk
Elżbieta Korobowicz
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0340-7

Other articles of this Issue 11/2007

Rheumatology International 11/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.